The UA Campus Repository is experiencing systematic automated, high-volume traffic (bots). Temporary mitigation measures to address bot traffic have been put in place; however, this has resulted in restrictions on searching WITHIN collections or using sidebar filters WITHIN collections. You can still Browse by Title/Author/Year WITHIN collections. Also, you can still search at the top level of the repository (use the search box at the top of every page) and apply filters from that search level. Export of search results has also been restricted at this time. Please contact us at any time for assistance - email repository@u.library.arizona.edu.
Artemisinin-Based Combination Anti-malarials Do Not Enhance Anti-melanoma Activity of Artemisinin-Monotherapy
| dc.contributor.advisor | Wondrak, Georg | en |
| dc.contributor.author | Jacobs, Suesan | |
| dc.contributor.author | Vonderfecht, Amanda | |
| dc.contributor.author | Wondrak, Georg | |
| dc.date.accessioned | 2016-06-22T21:48:52Z | |
| dc.date.available | 2016-06-22T21:48:52Z | |
| dc.date.issued | 2013 | |
| dc.identifier.uri | http://hdl.handle.net/10150/614262 | |
| dc.description | Class of 2013 Abstract | en |
| dc.description.abstract | Specific Aims: To determine if melanoma cells are more vulnerable to Amodiaquine (AQ) or Lumefantrine (LF)-based artemisinin combination therapy compared to artemisinin monotherapy. Methods: Tested anti-malarials in vitro for anti-melanoma activity, which contained 100,000 of the A375 human metastatic melanoma cells that were repeatedly treated independently three times. Main Results: Dihydroartemisinin (DHA) monotherapy induced significant cell death in melanoma cells. However, artemisinin combination therapy (ACT) did not enhance DHA-induced cell death. AQ protected against DHA-induced cell death causing morphological changes detected by electron microscopy. As for LF, it did not affect DHA-induced cell death. Conclusion: The results demonstrated that ACT does not display enhanced anti-melanoma activity compared to artemisinin monotherapy. It suggests that AQ may have anti-oxidant properties, but would need to be explored further in the context of anti-oxidant cyto-protection. | |
| dc.language.iso | en_US | en |
| dc.publisher | The University of Arizona. | en |
| dc.rights | Copyright © is held by the author. | en |
| dc.rights.uri | http://rightsstatements.org/vocab/InC/1.0/ | |
| dc.subject | Amodiaquine (AQ) | en |
| dc.subject | Lumefantrine (LF) | en |
| dc.subject | Artemisinin-Monotherapy | en |
| dc.subject | Anti-melanoma | en |
| dc.subject.mesh | Amodiaquine | |
| dc.subject.mesh | Lumefantrine | |
| dc.subject.mesh | Melanoma | |
| dc.title | Artemisinin-Based Combination Anti-malarials Do Not Enhance Anti-melanoma Activity of Artemisinin-Monotherapy | en_US |
| dc.type | text | en |
| dc.type | Electronic Report | en |
| dc.contributor.department | College of Pharmacy, The University of Arizona | en |
| dc.description.collectioninformation | This item is part of the Pharmacy Student Research Projects collection, made available by the College of Pharmacy and the University Libraries at the University of Arizona. For more information about items in this collection, please contact Jennifer Martin, Librarian and Clinical Instructor, Pharmacy Practice and Science, jenmartin@email.arizona.edu. | en |
| html.description.abstract | Specific Aims: To determine if melanoma cells are more vulnerable to Amodiaquine (AQ) or Lumefantrine (LF)-based artemisinin combination therapy compared to artemisinin monotherapy. Methods: Tested anti-malarials in vitro for anti-melanoma activity, which contained 100,000 of the A375 human metastatic melanoma cells that were repeatedly treated independently three times. Main Results: Dihydroartemisinin (DHA) monotherapy induced significant cell death in melanoma cells. However, artemisinin combination therapy (ACT) did not enhance DHA-induced cell death. AQ protected against DHA-induced cell death causing morphological changes detected by electron microscopy. As for LF, it did not affect DHA-induced cell death. Conclusion: The results demonstrated that ACT does not display enhanced anti-melanoma activity compared to artemisinin monotherapy. It suggests that AQ may have anti-oxidant properties, but would need to be explored further in the context of anti-oxidant cyto-protection. |